FIELD: biotechnology.
SUBSTANCE: bispecific antibody against rabies virus is proposed. The bispecific antibody contains two antigen-binding fragments that bind with epitope I and epitope III of G-protein of rabies virus and has activity neutralizing rabies virus. The invention also relates to a pharmaceutical composition including the specified antibody and a method for the prevention or treatment of rabies.
EFFECT: obtaining a bispecific antibody against rabies virus.
8 cl, 14 dwg, 4 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| HUMAN TSLP ANTIBODIES AND USE THEREOF | 2021 |
|
RU2825460C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO SOST, AND ITS USE | 2018 |
|
RU2779430C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | 2018 |
|
RU2766590C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND ITS USE | 2020 |
|
RU2811431C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO LAG-3 AND ITS USE | 2018 |
|
RU2771384C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY, AND USE THEREOF | 2020 |
|
RU2824390C2 |
